Dongkook Pharmaceutical Launches New TV Commercial for Gum Treatment "Insadol" Featuring Singer Yoon Jongshin

Dongkook Pharmaceutical announced on February 4 that it has aired a new TV commercial for its gum treatment “Insadol,” featuring singer Yoon Jongshin as the new model.

The new commercial is structured as a natural conversation, starting from the story of how they began taking Insadol and moving on to discuss the product’s effects and their satisfaction with it.

Dongkook Pharmaceutical Insadol TV commercial screenshot. Dongkook Pharmaceutical

In the new advertisement, Yoon Jongshin says, “Oh, Insadol? I take it too. My gums used to bother me when they weren’t in good condition, but they’ve gotten better,” referring to the changes in his daily life after taking Insadol. Then Lee Boyoung says, “It feels like strength is building from deep inside my gums,” highlighting the product’s efficacy in strengthening the alveolar bone, the tissue that holds the teeth in place within the gums. Kim Seungwoo adds, “If you take it consistently, it really becomes comfortable,” conveying his satisfaction with the choice.

In addition, the voice-over narration and subtitles emphasize that the product has “obtained marketing authorization from Swissmedic,” enhancing trust in the product. Yoon Jongshin’s confident line, “I’m glad I started, Insadol,” further delivers the key message that “Insadol is for gum care.”

A marketing representative at Dongkook Pharmaceutical said, “This TV commercial is structured in an interview format, where singer Yoon Jongshin, as the new model, naturally shares his own thoughts on the effects of Insadol that he experienced after choosing the product,” adding, “By featuring existing models Lee Boyoung and Kim Seungwoo, we aimed to convey confidence in the Insadol brand, emphasize the importance of gum health care, and strengthen trust in the product.”

Dongkook Pharmaceutical’s herbal-ingredient gum treatment “Insadol” obtained over-the-counter marketing authorization from the Swiss Agency for Therapeutic Products (Swissmedic) in January 2024. By having its effectiveness for early gum inflammation and other initial periodontal diseases recognized by a regulatory authority in a leading pharmaceutical country, the product has significantly enhanced the status of K-pharmaceuticals. Building on this, the company plans to work on expanding into European and other overseas markets, starting with Insadol exports to Switzerland.

This content was produced with the assistance of AI translation services.